John Blankenhorn

John Blankenhorn

Expertise: Biochemistry, biotechnology and pharmaceutical research

John Blankenhorn has been a researcher since 2016 and has years of experience and publications on the topics of biochemistry, biotechnology, and pharmaceutical research. His main interests are the application of biology and biotechnology to our daily lives, as well as the use of Machine Learning and AI to speed up research and development in the life sciences. He currently works at Emory University studying the structural basis of Alzheimer’s Disease.

Recent Articles

The 3 Most Promising Biotech Stocks to Buy Now

Bruker, Qiagen, and Bio-Rad are three of the most promising healthcare stocks to buy as NIH funding increases.

3 Cutting-Edge Healthcare Stocks That Can Pay Off Big Time

For investors betting on healthcare, look for these three companies to provide the treatments of tomorrow.

3 Vaccine Stocks to Watch for Their Post-Pandemic Moves

The vaccine stocks Pfizer, Moderna, and Novavax all have approved Covid-19 vaccines. They'll soon need new sources of revenue.

3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing

CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals are three CRISPR gene editing stocks you won't want to miss out on.

3 Drug Stocks to Watch as Alzheimer’s Clinical Trials End

These drug companies are running clinical trials for Alzheimer's drugs. The cure is worth billions, so these are the drug stocks to watch.